Preoperative radiation improved T-cell infiltration in patients with HR+ HER2- breast cancer when administered in combination ...
Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell ...
The results from HER2CLIMB-05 study, presented at the 2025 SABCS annual meeting, demonstrated that tucatinib (TUKYSA) added ...
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
Arcellx’s Phase 2 iMMagine 1 trial of anito cel in heavily pretreated multiple myeloma delivered a 96% response rate, 74% ...
New clinical data presented at the 67th ASH Annual Meeting indicated that Lunsumio could be a strong candidate for earlier ...
Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback